Biotoxtech

[Available On-Demand] ・ Click video to start playback; Join chat Q&A below video
Search General Info
Biotoxtech is a life science company and a non-clinical CRO head-quartered in Korea. Biotoxtech has the experience of submitting hundreds of documents to the regulatory agencies of US, Japan, Europe, etc. In 2015, the US FDA GLP inspection was held, and Biotoxtech received approval for the first time among domestic private non-clinical CROs.
Biotoxtech offers general toxicity, genotoxicity, safety pharmacology, developmental toxicology, carcinogenicity and histopathology services, etc. Biotoxtech also provides reliable efficacy testing services with customized study design, and conducts PK evaluation of new drug candidate and PCR-based bio-distribution studies for gene and cell-based therapeutics.
Recently, Biotoxtech try to expand business to proprietary drug development using their experience in non-clinical development. Several drug pipelines including BTT-105 (NASH therapeutics) and BTT-0811 (myocardial infarction, alopecia) completed Phase I trials and wait for Phase II trials.
Ticker:
086040
Exchange:
KOSDAQ
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
BTT-105, BTT-0811
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
General manager
Biotoxtech. Co. Ltd